March 3, 2011 | Filed under: Health,News | Posted by:
The new breast cancer drug eribulin (Halaven) extends survival two and a half months longer than other therapies for advanced breast cancer, researchers report.
Posted by
on March 3, 2011. Filed under Health, News.
You can follow any responses to this entry through the RSS 2.0.
You can leave a response or trackback to this entry
Posted by
on March 3, 2011. Filed under